Samira M. Sadowski, M.D.
- Center for Cancer Research
- National Cancer Institute
- Building 10 CRC, Room 4-5932
- Bethesda, MD 20892
Dr. Sadowski’s research focuses on the identification of diagnostic and prognostic markers for endocrine tumors and developing new therapies for such tumors. She has extensive experience in the field of endocrine surgery.
Areas of Expertise
Information for Patients
Learn more about our clinical trials and the highly specialized care teams that lead them.
Neuroendocrine tumors are a diverse and increasingly common set of cancers. While some of these tumors are known to have a hereditary component, in general they are understudied and often fatal.
Dr. Sadowski’s work addresses the critical gaps in our knowledge of the basic mechanisms of neuroendocrine tumor biology, such as the high variability in receptor density and treatment response in patients with identical histology and tumor grade or the difficulties in detecting disease. She is seeking to uncover new therapies for neuroendocrine tumors in order to improve patient survival. To this end, she intends to establish a reproducible model for neuroendocrine tumor research and elucidate regulation of the neuroendocrine tumor surface receptor repertoire.
Dr. Sadowski’s translational and clinical investigations have three main goals: 1) to develop effective therapies for rare and neglected endocrine cancers, 2) to identify new methods, strategies and technologies for improving the diagnosis and prognostication of endocrine neoplasms, and 3) to develop methods for personalized precision treatment of endocrine tumors.
Identification of Differential Transcriptional Patterns in Primary and Secondary Hyperparathyroidism
Association of the VHL Genotype with Pancreatic Neuroendocrine Tumor Phenotype in Patients with Von Hippel-Lindau Disease
Prospective Study of 68Ga-DOTATATE Positron Emission Tomography/Computed Tomography for Detecting Gastro-Entero-Pancreatic Neuroendocrine Tumors and Unknown Primary Sites
Feasibility of Radioguided Surgery with 68Gallium-DOTATATE in Patients with Gastro-Entero-Pancreatic Neuroendocrine Tumors
Torin2 targets dysregulated pathways in anaplastic thyroid cancer and inhibits tumor growth and metastasis
Samira M. Sadowski, M.D.
Dr. Sadowski received her medical training at the University of Geneva, Switzerland. She completed her general surgery residency training at the University Hospitals of Geneva and received a master's degree in medical biostatistics at the University of Montreal, Canada. She completed her endocrine oncology surgery fellowship at the National Institutes of Health. Dr. Sadowski was on faculty at the University Hospitals of Geneva before being recruited to the NCI.
There are no open positions at this time. Check back again later, or take a look at CCR's Careers page.